S-1/A: Functional Brands Faces Going Concern Warning Amidst Direct Listing and Mounting Debt

Functional Brands Inc., a nutraceutical and hemp-derived product manufacturer, is pursuing a direct listing on Nasdaq while grappling with recurring losses, negative cash flows, and a significant accumulated deficit, prompting an auditor's going concern warning.

Summary

• Functional Brands Inc. (formerly HT Naturals Inc.) is seeking a direct listing on the Nasdaq Capital Market under the symbol MEHA, with an expected trading commencement on or about July __, 2025.
• The company operates in two primary segments: nutraceuticals under the Kirkman brand (established 1949, over 150 products, FDA registered, cGMP certified facility) and hemp-derived products under the HempTown Naturals and Golf Mellow brands (2018 Farm Bill compliant).
• A key product launch is the P2i by Kirkman prenatal vitamin, which is highlighted as the only certified prenatal vitamin aligning with the International Federation of Gynecology and Obstetrics (FIGO) October 2023 position statement on low-toxicity standards.
• For the three months ended March 31, 2025, net revenue decreased by 8% to $1,590,258 from $1,722,499 in the prior year period, primarily due to lower demand from contract manufacturing customers.
• The company reported a net loss of $126,781 for Q1 2025, a significant decrease of 258% compared to a net income of $80,132 in Q1 2024.
• Operating expenses increased by 20% in Q1 2025 to $898,868, driven by increased selling and marketing costs (up 32%) and general and administrative expenses (up 17%).
• For the year ended December 31, 2024, net revenue decreased by 4% to $6,566,455 from $6,820,499 in 2023.
• The net loss for FY 2024 was $559,356, a 55% reduction from the $1,241,094 net loss in FY 2023, attributed to cost control measures.
• As of March 31, 2025, the company had an accumulated deficit of $7,787,711 and total current liabilities of $5,259,788 against total current assets of $3,184,865.
• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and accumulated deficit.
• The company has a significant outstanding debt of $2,227,366 related to the Kirkman acquisition, which is due by August 30, 2025, and is subject to a confession of judgment allowing foreclosure upon default.
• A private placement of Series A and Series B Convertible Preferred Stock, totaling $8,000,000 in funding, is conditioned upon the completion of the Direct Listing, with proceeds intended to cure the acquisition debt and fund working capital.
• The company relies heavily on two major customers, iHerb and OceanSide Health, which accounted for 54% of total revenue in 2024.
• The direct listing process, unlike a traditional IPO, lacks firm-commitment underwriting, potentially leading to higher price and volume volatility and an uncertain trading market.

Sentiment

Score: 3

Explanation: The company faces severe financial distress, evidenced by recurring losses, a significant accumulated deficit, and an auditor's going concern warning. While it possesses a strong legacy brand and innovative new products, its immediate future is highly dependent on a successful, high-risk direct listing and a capital raise to address critical debt obligations and liquidity shortfalls. The declining revenue and increasing expenses in the most recent quarter further underscore the challenges.

Positives

• The Kirkman brand has a 70+ year history with a loyal consumer base, operating in 95% of major supplement subsegments.
• Manufacturing facility is FDA registered and cGMP certified, adhering to high purity and quality standards, including testing every batch for heavy metals and microbial contamination, exceeding FDA requirements for dietary supplements.
• The P2i by Kirkman prenatal vitamin is uniquely certified by The FORUM, aligning with FIGO's low-toxicity standards, positioning it as a differentiated product in the market.
• The company has an exclusive license agreement with 'Trailer Park Boys' for marketing hemp-derived products, which could leverage brand recognition.
• Strategic growth plans include strengthening existing brands, launching new niche brands (P2i, Golf Mellow), modernizing manufacturing, and increasing sales and marketing investments.
• Net loss decreased by 55% in FY 2024 compared to FY 2023, indicating some success in cost containment and stabilization efforts.
• Cash provided by operating activities increased significantly in Q1 2025 to $175,994, compared to cash used of $20,425 in Q1 2024.

Negatives

• The company has suffered recurring losses from operations, with a net loss of $126,781 in Q1 2025 and $559,356 in FY 2024.
• A significant accumulated deficit of $7,787,711 as of March 31, 2025, raises substantial doubt about the company's ability to continue as a going concern, as noted by its independent auditor.
• Net revenue decreased by 8% in Q1 2025 and 4% in FY 2024, primarily due to lower demand from contract manufacturing customers.
• Operating expenses increased by 20% in Q1 2025, driven by higher selling and marketing costs (32% increase) and general and administrative expenses (17% increase).
• The company has significant outstanding debt, including $2,227,366 for the Kirkman acquisition, which is due by August 30, 2025, and is backed by a confession of judgment allowing foreclosure upon default.
• Current cash and cash flow from operations are projected to be sufficient for only the next six months, necessitating additional financing.
• Reliance on two major customers (iHerb and OceanSide Health) for 54% of 2024 revenue poses a concentration risk.
• The direct listing process is described as novel and potentially more volatile than a firm-commitment underwritten initial public offering, with no fixed number of shares for sale or traditional roadshow.
• Hemp-derived products, despite brand licensing, represent a very small portion of total company revenue (0.6% from Trailer Park Boys licensed products).
• The regulatory environment for hemp and CBD products is uncertain and evolving, posing a significant risk to this business segment.
• The company has a limited operating history under its current structure (Functional Brands Inc. organized in Nov 2020).

Risks

• The independent registered public accounting firm has expressed substantial doubt about the company's ability to continue as a going concern.
• Inability to effectively manage future growth, potentially straining operational and financial systems.
• Requirement for additional financing in the future, which may not be available when needed or could be costly and dilutive to existing shareholders.
• If unable to continue as a going concern, securities will have little or no value.
• Limited operating history may hinder successful business operation or execution of the business plan.
• Potential to incur significant debt to finance operations, with no assurance of sufficient funds for repayment.
• Existing events of default under the Asset Purchase Agreement for the Kirkman acquisition could lead to foreclosure on company assets.
• Intense competition in the brand-conscious nutraceutical and hemp industries from larger, well-financed manufacturers and distributors.
• Inability to maintain a positive brand image, especially due to negative public perception or product quality issues in the hemp industry.
• Failure to adapt to rapid changes in consumer preferences and public perception in the industry.
• Inability to respond effectively to technological changes, potentially reducing demand for products.
• Reduced demand for smokable products due to health concerns and legislative initiatives.
• Legislative or regulatory changes, including new taxes on products, could reduce demand or increase costs.
• Uncertain and evolving federal, state, and local regulations concerning hemp, CBD, CBG, and other non-tobacco consumable products.
• International expansion efforts would likely significantly increase operational expenses and regulatory risks.
• Reliance on distributors, retailers, and brokers could affect efficient and profitable distribution and market expansion.
• Loss of key distributors or retail accounts would harm the business.
• Pandemics, such as COVID-19, could continue to negatively affect various aspects of the business, including supply chains and demand.
• Reliance on third-party suppliers, manufacturers, and contractors, with events adversely affecting them impacting the company.
• Concentration of revenues from two major customers (iHerb and OceanSide Health), making the business vulnerable to their loss.
• Wholesale price volatility for hemp and other product ingredients may adversely affect operations and profitability.
• Potential for uninsured liabilities and losses, as current liability insurance coverage may be inadequate.
• Exposure to product liability claims and other claims from customers and partners, which could be costly and damage reputation.
• Product recalls or other product quality issues could negatively affect profitability and brand image.
• Difficulty in predicting the timing and amount of sales, leading to uncertain sales forecasts.
• Inadequate inventory management could adversely affect operating results and customer relationships.
• Increases in costs or shortages of raw materials could harm business and financial results.
• Increases in energy costs and increased regulations may adversely impact gross margin.
• Disruption within the supply chain, contract manufacturing, or distribution channels could have an adverse effect.
• Inability to attract and retain key personnel, including the Chief Executive Officer and Chief Financial Officer.
• Failure to protect trademarks and trade secrets could hinder successful product marketing and competition.
• Disruptions to information technology systems due to cyber-attacks or failure to upgrade may materially impair operations.
• Business is subject to many regulations, and noncompliance is costly.
• Significant additional labeling or warning requirements may inhibit sales of affected products.
• Industry may become subject to expanded regulation and increased enforcement by the FDA and FTC.
• Results of operations may fluctuate from quarter to quarter due to seasonality and other factors.
• Global economic, political, social, and other conditions (e.g., geopolitical conflicts) may adversely impact business.
• Changes in accounting standards and subjective assumptions/estimates by management could significantly affect financial results.
• Transition to a new presidential administration in the United States, including potential tariffs, could materially impact the macroeconomic framework.
• Significant tariffs or other restrictions imposed on imports by the U.S. and related countermeasures could have a material adverse effect.
• The direct listing process differs significantly from an initial public offering, potentially leading to greater price and volume volatility.
• No assurance that the company will satisfy Nasdaq listing requirements or maintain a listing.
• Difficulty for plaintiffs to make Section 11 claims under the Securities Act in a direct listing due to traceability challenges.
• Future sales of common stock by Registered Stockholders and other existing stockholders could cause share price to decline.
• Future issuances of preferred stock or additional common stock could result in dilution of existing holdings.
• No current plans to pay cash dividends, meaning shareholders may only receive a return through stock sales.
• Lack of research reports from securities industry analysts could negatively affect market price and trading volume.
• Authorization to issue blank check preferred stock without stockholder approval could adversely impact common stock rights.
• If the stock price falls below $5.00 and is not listed on a national exchange, it could become subject to penny stock rules, making trading more difficult.
• Reduced disclosure requirements as an emerging growth company and smaller reporting company may make common stock less attractive to investors.
• The company will not receive any proceeds from the direct listing, as sales are by Registered Stockholders.

Future Outlook

Functional Brands aims to become a leader in the nutraceutical space by upholding high quality standards for products, expanding its portfolio to include mushroom-based supplements, prenatal, and athlete-focused products. The company plans to strengthen its existing Kirkman brand, launch new brands like P2i by Kirkman and Golf Mellow, modernize manufacturing capabilities, and significantly increase sales and marketing efforts. It also intends to identify synergistic partnerships or acquisitions. The company anticipates needing approximately $3.6 million for working capital and capital expenditures over the next twelve months, acknowledging that current cash and cash flow will only suffice for the next six months, thus planning to seek additional equity or debt financing. The company expects its common stock to begin trading on Nasdaq on or about July __, 2025, under the symbol MEHA. Management expects continued operating losses if sustained revenue targets are not met.

Management Comments

• "We aim to be a leader in the nutraceutical space by manufacturing products held to the highest standard of quality in terms of toxins, metals, and other impurities."
• "Our goal is to build a well-rounded portfolio of products including mushroom-based supplements targeted for everyday use, prenatal, athletes and beyond."
• "We believe it is imperative that we meet these sales objectives in order to lessen our reliance on external financing in the future."
• "We intend to continually monitor and adjust our operating plan as necessary to respond to developments in our business, our markets and the broader economy."
• "We do not know of any trends, demands, commitments, events or uncertainties that will result in, or that are reasonable likely to result in, our liquidity increasing or decreasing in any material way."
• "We do not know of any significant changes in expected sources and uses of cash."
• "Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause an effect on our results of operations, financial position or liquidity for the periods presented in this report."

Industry Context

Functional Brands operates within the dynamic nutraceutical supplement and emerging hemp-derived product industries. The global nutritional supplements market was valued at approximately $405.15 billion in 2023, with a projected CAGR of 6.3% through 2030, driven by increasing health awareness and the rising prevalence of non-communicable diseases. The U.S. market for nutritional supplements is a significant contributor, valued at $95.2 billion in 2023, with a 4.8% CAGR. Similarly, the U.S. dietary supplement market is robust at $53.6 billion in 2023, growing at 5.7% CAGR. The global prenatal vitamin supplement market, a specific focus for Functional Brands with its P2i product, was valued at $542.8 million in 2023 and is projected to grow at an 8.5% CAGR. The global CBD consumer health market, where Functional Brands also operates, was valued at $19.5 billion in 2023 and is expected to grow at an 18.1% CAGR, largely due to increasing legalization and awareness of health benefits. However, the FDA's regulatory pathway for CBD products remains uncertain, awaiting Congressional direction, which introduces significant regulatory risk and variability in state-level regulations for hemp-derived products.

Comparison to Industry Standards

• The Kirkman brand's 70+ year history positions it as one of the oldest and most established companies in the nutritional supplement industry, particularly serving the special needs community.
• Kirkman's manufacturing facility is FDA registered and cGMP certified, and the company's practice of testing every batch of products for heavy metals (below Prop 65 limits) and microbial contamination, and raw materials for approximately 90 metals and toxins, exceeds the FDA's general requirements for dietary supplements, which do not mandate such testing.
• The P2i by Kirkman prenatal vitamin is highlighted as the unique 'only certified prenatal vitamin in the market that aligns to the FIGO position statement' from October 2023, setting a high standard for low-toxicity and safety in a market with approximately 3.6 million pregnancies annually in the U.S.
• In the multi-vitamin segment, Kirkman competes with market leaders such as private label store brands, Nature Made, Centrum, One-A-Day, and Nature's Bounty.
• Within the broader supplement category (e.g., Digestive Health, General Health), key competitors include Nature's Bounty, Nature Made, Emergen-C, Baush+Lomb, and Airbourne.
• In the specialized 'special needs' supplement category, Kirkman competes with companies like New Beginnings, Claire Labs, Houston Enzymes, and Lifetrients.
• In the hemp industry, Functional Brands competes with established CBD product companies such as Charlotte's Web, cbdMD, Social CBD, Joy Organics, and MedTerra, noting that market share data is limited due to prevalent online sales.

Management Changes

Corporate Governance

Legal Proceedings

• True Health Medical Center, S.C. (True Health) amended an existing complaint on May 25, 2021, to assert claims against HTO Nevada, Inc. and HTO Holdings, Inc. (collectively, the HTO Parties), in addition to Kirkman Group, Inc., James Hall, and David Humphries.
• The case is pending in the Circuit Court for the Eighteenth Judicial Circuit, DuPage County, Illinois.
• True Health alleges that Kirkman underpaid royalties due to True Health prior to the sale of assets to the HTO Parties, and contends that the HTO Parties, as purchasers of certain Kirkman assets, should be bound by the royalty agreement terms.
• There is no certain amount of damages claimed against the HTO Parties at this time.
• Discovery, including depositions, has largely been completed, but Kirkman Group recently filed a motion for leave to amend its counterclaims against True Health (not against HTO Nevada).
• If amended counterclaims are permitted, additional discovery and motion practice are likely, which would typically delay the prospective trial date.
• No trial date has been scheduled at this time.

Related Party Transactions

• On March 7, 2025, the company executed a loan agreement with Eric Gripentrog (Chief Executive Officer) for $225,000, with an 18% annual interest rate and a maturity date of March 7, 2029.
• On March 11, 2024, the company executed a loan agreement with Eric Gripentrog (Chief Executive Officer) for $130,000, with a 20% annual interest rate and a maturity date of March 10, 2031.
• In December 2023, the company entered into a short-term debt facility with a related party (an officer and director of the parent company, Hemptown Organics Corp.) for $247,634, which is non-interest-bearing and remains outstanding as of March 31, 2025.
• The acquisition of HTO Nevada Inc. dba Kirkman by Functional Brands on May 19, 2023, involved a share exchange agreement with Hemptown Organics Corp. (HOC) and its wholly-owned subsidiary HTO Holdings Inc., resulting in HTO Nevada becoming a wholly-owned subsidiary of Functional Brands.
• Functional Brands has a perpetual, non-exclusive, non-transferable license agreement with Hemptown Organics Corp. (dated December 10, 2020) to use the Hemptown USA and Hemptown Naturals brands and trademarks, which will transfer to full ownership upon the effective date of the registration statement and listing.
• The company has an exclusive license agreement with Trailer Park Boys Incorporated (TPB), effective July 21, 2021, and expiring December 31, 2025, under which the company will pay TPB $700,000 ($525,000 paid to date) and 1,000,000 shares of common stock, plus royalties of 15-30% of gross sales.
• On June 25, 2025, the company issued 18,082 shares of its common stock as settlement for interest owed to a debenture holder of Hemptown Organics Corp. (HOC).

Stakeholder Impact

• Shareholders face significant risks including potential dilution from future equity issuances (preferred stock, incentive plans, acquisitions), high volatility of the common stock due to the direct listing process, and the absence of planned cash dividends, meaning returns are solely dependent on stock appreciation.
• Existing shareholders (Registered Stockholders) may sell their shares immediately upon listing, potentially leading to an oversupply and downward pressure on the stock price.
• Employees are impacted by the company's ability to attract and retain key personnel, particularly the CEO and CFO, whose continued services are crucial for business operations and strategic execution.
• Customers may experience impacts from product quality issues or recalls, and the company's high revenue concentration with two major customers (iHerb and OceanSide Health) creates a dependency risk.
• Suppliers and creditors face risks related to the company's financial health, including its recurring losses and significant outstanding acquisition debt, which is subject to a confession of judgment allowing foreclosure upon default if not cured.
• Regulatory bodies are actively involved in overseeing the nutraceutical and hemp industries, and the company's compliance with evolving federal and state regulations (e.g., FDA, FTC, state hemp laws) is critical to avoid fines, production halts, and reputational damage.

Next Steps

• Complete the Direct Listing on the Nasdaq Capital Market under the symbol MEHA.
• Secure funding from the private placement of Series A and Series B Convertible Preferred Stock, which is conditioned on the Direct Listing.
• Utilize a portion of the private placement proceeds to cure the $2,227,366 outstanding acquisition debt by the extended due date of August 30, 2025.
• Allocate remaining private placement proceeds to sales, marketing, and general working capital.
• Strengthen the existing 70-year-old Kirkman brand by curating its product mix to cater to specific consumer needs, particularly within the autism community.
• Launch and expand new brands, including P2i by Kirkman (prenatal vitamin) and the Golf Mellow line of supplements.
• Modernize manufacturing capabilities by reorganizing space and introducing new and efficient machinery and equipment to enhance output.
• Invest heavily in sales and marketing activities, as well as business development, to increase sales and distribution.
• Identify key companies with synergistic strengths for potential partnerships or acquisitions.
• Seek additional equity and/or debt financing in the future to support working capital needs beyond the next six months.
• Monitor and adjust the operating plan as necessary in response to developments in the business, markets, and broader economy.
• Continue to engage specialized hemp counsel to monitor and ensure compliance with evolving federal and state regulations concerning hemp-derived products.
• Address the ongoing legal proceedings with True Health Medical Center, S.C., including potential additional discovery and motion practice.

Key Dates

Recommendation

Keywords

Nutraceuticals, Supplements, Hemp, CBD, CBG, Direct Listing, Nasdaq Capital Market, SEC Filing, S-1/A, Kirkman, P2i, Golf Mellow, Financial Performance, Going Concern, Capital Raise, Risk Factors, Corporate Governance, FDA Regulation, Supply Chain, Market Volatility, Private Placement